McIntyre RS

Department of Pharmacology and Toxicology, University of Toronto, Toronto, Canada; Department of Psychiatry, University of Toronto, Toronto, Canada. Electronic address: roger.mcintyre@bcdf.org.

McIntyre RS

Pharmacological, clinical, and translational evidence for N,N-dimethyltryptamine, 5-methoxy-N,N-dimethyltryptamine, and zalsupindole: a systematic review.

Cognitive effects of ketamine and esketamine treatment for major depressive and bipolar disorder: a systematic review.

The effect of ketamine on mitochondrial bioenergetics, viability, and function: A systematic review.

Serial Ketamine Infusions for Treatment-Resistant Bipolar Depression: A Randomized Clinical Trial.

Psychedelics in psychiatry: comparative effectiveness, implementation, commercialization and safety lessons learned from intranasal esketamine.

A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression.

Adjunctive Pharmacotherapy for Major Depressive Disorder with Anxiety Symptoms: from Monoamines to Recent Clinical Evidence.

A scoping review: ketamine or esketamine when used to assist psychotherapy or in combination with psychotherapy for the management of depression in adults.

Elunetirom, a brain-targeted TRβ prodrug, promotes neuronal plasticity and mitochondrial biogenesis-related signaling in primary neuronal cultures

Ketamine Infusions and Rapid Reduction of Suicidal and Depressive Symptoms in Major Depressive Episode: A Systematic Review and Meta-Analysis.

Blinding Integrity in Psychedelic Randomized Clinical Trials: A Systematic Review.

Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review.

Trajectory of response to esketamine nasal spray for treatment resistant depression: Findings from ESCAPE-TRD.

The Serotonin 2B (5-HT2B) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression.

Structural Neurotoxic and Neuroprotective Effects of Ketamine and Esketamine in Preclinical and Human Studies: A Systematic Review

Evaluating the potential risk of ketamine-induced hepatotoxicity in the treatment of mood and anxiety disorders: A systematic review.

Effect of ketamine on reward processing in depressive disorders: a systematic review of neuroimaging studies.

Are the current safety measures for the treatment of depression with esketamine sufficient?

The use of repetitive transcranial magnetic stimulation (rTMS), electroconvulsive therapy (ECT), ketamine, and esketamine in reducing suicidality in major depressive disorder: A comprehensive narrative review.

The effect of glutamatergic modulators on sleep behavior and architecture in depressive disorders: A systematic review.

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression.

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.

Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?

Modulating tonic NMDA receptor currents: mechanistic insights into ketamine, esketamine, and dextromethorphan for major depressive disorder and implications for the discovery and development of investigational agents.

Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy.

Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial report.

A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals?

The effect of dextromethorphan on reward-related behaviors: A systematic review of preclinical and clinical evidence.

Effects of Intravenous Ketamine on Posttraumatic Stress Disorder (PTSD): A Systematic Review.

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial.

The effects of ketamine and esketamine on functional outcomes in major depressive disorder and treatment-resistant depression: A systematic review.

A Systematic Review of the Effects of N-Methyl-D-Aspartate Receptor Antagonists on Pancreatic Islets.

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models.

Durability of the Benefit of Vagus Nerve Stimulation in Markedly Treatment-Resistant Major Depression: A RECOVER Trial Report

Comment on Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis.

Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal.

Safety and Efficacy of the NMDA-2b-Selective Negative Allosteric Modulator BI 1569912: A Phase Ib Randomized Trial in Major Depressive Disorder.

Biased agonism in psychopharmacology: an opportunity to improve efficacy and safety of treatments.

Ketamine and Esketamine for Late-Life Depression: A Systematic Review of Efficacy, Safety, and Tolerability.

Effectiveness of repeated Esketamine nasal spray administration on anhedonic symptoms in treatment-resistant bipolar and unipolar depression: A secondary analysis from the REAL-ESK study group.

A Global Population-Based Study on the Association Between Ketamine and Esketamine With Suicidality Using WHO VigiBase.

Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression.

Should glutamatergic modulators be considered preferential treatments for adults with major depressive disorder and a reported history of trauma? Conceptual and clinical implications.

Non-hallucinogenic psychedelics for mood and anxiety disorders: A systematic review.

The Effects of Ketamine and Esketamine on Measures of Quality of Life in Major Depressive Disorder and Treatment-Resistant Depression: A Systematic Review.

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder.

Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study.

Demystifying the Antidepressant Mechanism of Action of Stinels, a Novel Class of Neuroplastogens: Positive Allosteric Modulators of the NMDA Receptor.

Esketamine nasal spray versus quetiapine XR in adults with treatment-resistant depression: a secondary analysis of the ESCAPE-TRD randomized clinical trial.

Hepatic adverse events associated with ketamine and esketamine: A population-based disproportionality analysis.

Functional Connectivity Between Glutamate Receptor Antagonism and Insulin Pathways: Implications for Modeling Mechanism of Action of Ketamine/Esketamine and Dextromethorphan in Depression Treatment.

Glutamatergic Modulators for Major Depression from Theory to Clinical Use.

A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists.

Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression.

The association between ketamine and esketamine and suicidality: reports to the Food And Drug Administration Adverse Event Reporting System (FAERS).

Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review.

The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS).

Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis.

Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review.

Predicting non-response to ketamine for depression: An exploratory symptom-level analysis of real-world data among military veterans.

Recent Advances in the Treatment of Treatment-Resistant Depression: A Narrative Review of Literature Published from 2018 to 2023.

A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review.

The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.

Augmentation in depression: Esketamine, a new standard?

The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review.

Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.

Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.

Exploring the potential of a bridge therapy: Synergistic approach integrating intravenous ketamine and intranasal esketamine for treatment-resistant depression.

Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).

Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.

Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.

Serotonin 5-HT<sub>2B</sub> receptor agonism and valvular heart disease: implications for the development of psilocybin and related agents.

The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review.

Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects.

Rethinking ketamine and esketamine action: Are they antidepressants with mood-stabilizing properties?

Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.

A Phase II, Open-Label Clinical Trial of Intranasal Ketamine for Depression in Patients with Cancer Receiving Palliative Care (INKeD-PC Study).

A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap.

A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review.